Department of Medicine, Boston Medical Center, 72 East Concord Street, Evans 124, Boston, MA 02118, United States of America.
Section of Infectious Diseases, Boston Medical Center, 801 Massachusetts Ave., Crosstown Center, 2nd Floor, Boston, MA 02118, United States of America.
J Subst Abuse Treat. 2022 Nov;142:108870. doi: 10.1016/j.jsat.2022.108870. Epub 2022 Sep 1.
Access to and uptake of evidence-based treatment for substance use disorder, specifically opioid use disorder (OUD), are limited despite the high death toll from drug overdose in the United States in recent years. Patient perceived barriers to evidence-based treatment after completion of short-term inpatient medically managed withdrawal programs (detox) have not been well studied. The purpose of the current study is to elicit patients' perspectives on challenges to transition to treatment, including medications for OUD (MOUD), after detox and potential solutions.
We conducted semi-structured interviews (N = 24) at a detox center (2018-2019) to explore patients' perspectives on obstacles to treatment. The study managed the data in NVivo and we used content analysis to identify themes.
Patients' characteristics included the following: 54 % male; mean age 37 years; self-identified as White 67 %, Black 13 %, Latinx 8 %, Native Hawaiian/Pacific Islander 4 %, and other 8 %; heroin use in the past 3 months 67 %; and ever injecting drugs 71 %. Patients identified the following barriers: 1) lack of continuity of care; 2) limited number of detox and residential treatment program beds; 3) unstable housing; and 4) lack of options when choosing a treatment pathway. Solutions proposed by participants included: 1) increase low-barrier access to community MOUD; 2) add case managers at the detox center to establish continuity of care after discharge; 3) increase assistance with housing; and 4) encourage patient participation in treatment decisions.
Patients identified lack of continuity of care, especially care coordination, as a major barrier to substance use treatment. Increasing treatment utilization, including MOUD, necessitates a multimodal approach to continuity of care, low-barrier access to MOUD, and support to address unstable housing. Patients want care that incorporates options and respect for. individualized preferences and needs.
尽管近年来美国因药物过量导致的死亡人数居高不下,但获得和接受基于证据的物质使用障碍治疗(特别是阿片类药物使用障碍[OUD])的机会仍然有限。在短期住院医疗管理戒断计划(戒毒)完成后,患者对基于证据的治疗的感知障碍尚未得到充分研究。本研究旨在了解患者在戒毒后过渡到治疗(包括 OUD 的药物治疗[MOUD])所面临的挑战,并探讨潜在的解决方案。
我们在一家戒毒中心(2018-2019 年)进行了半结构化访谈(N=24),以探讨患者对治疗障碍的看法。研究在 NVivo 中管理数据,我们使用内容分析来确定主题。
患者的特征包括:男性占 54%;平均年龄 37 岁;自认为白人占 67%,黑人占 13%,拉丁裔占 8%,夏威夷原住民/太平洋岛民占 4%,其他种族占 8%;过去 3 个月内使用海洛因占 67%;过去曾注射毒品占 71%。患者确定了以下障碍:1)缺乏连续性护理;2)戒毒和住院治疗项目床位数量有限;3)住房不稳定;4)在选择治疗途径时缺乏选择。参与者提出的解决方案包括:1)增加社区 MOUD 的低门槛获取途径;2)在戒毒中心增加个案经理,以在出院后建立连续性护理;3)增加住房援助;4)鼓励患者参与治疗决策。
患者确定缺乏连续性护理,特别是护理协调,是物质使用治疗的主要障碍。要增加治疗利用率,包括 MOUD,需要采用多模式方法来实现连续性护理、增加 MOUD 的低门槛获取途径,并提供支持以解决住房不稳定问题。患者希望得到能够结合各种选择并尊重个性化偏好和需求的护理。